Neuroinflammation Pipeline Enables Patient Selection


  • Chronic neuroinflammation, inflammation in the brain or spinal cord, correlates with poor outcomes in a wide range of diseases (e.g. ALS, MS, Alzheimer’s, Parkinson’s)

  • Neuroinflammation is difficult to diagnose, and current diagnostics lack sufficient selectivity


  • Developed a biomarker (18F-OP-801) that is selectively taken up by activated microglia in regions of neuroinflammation in multiple animal models
  • Provides a method to measure nanomedicine uptake in the brain to select patients
  • Because all HDs distribute the same way in the body, the amount of 18F-OP-801 in the brain provides an estimate of the amount of nanomedicine that will get to the same cells in the brain
  • Our nanomedicines have been observed to cross BBB in 7 animal species only when neuroinflammation is present

Leveraging OP-801 to Achieve Human POC

Ability to Ensure Nanomedicines Target Diseased Brain Tissues

Ability to Ensure HDT Targets Diseased Brain Tissues - Ashvattha

18F-OP-801 (18F-HD) Increases Trial Success: Patient Selection, HD Target Engagement

18F OP-801 Increases Trial Success Patient Selection HD Target Engagement

Selective Targeting to Neuroinflammation in Alzheimer’s Disease Mice

Neuroinflammation in Mice

OP-801: Phase 1/2 Proof of Targeting Neuroinflammation in ALS Patients

Phase 1/2 – Age Matched Healthy Volunteers and ALS Patients

  • Safety & Tolerability of 18F-OP-801 (IV dose)
  • Pharmacokinetics & Dosimetry of 18F-OP-801
  • Optimize PET scan for future studies – Optimal Dose & Scan Time
  • ALS vs Normal Healthy Adults PET images – Demonstration of Selectivity
    (analogous to 5xFAD mouse data)


  • LPI in 2H 2023

Expand to Image-Treat-ReImage Study in 2024